The debate over telerobotic surgery is shifting from feasibility to scalability, and SS Innovations International (NASDAQ: SSII) is emerging as a central player in that transition. A recent MedTech Dive article examined the technology’s global development and the regulatory and infrastructure questions surrounding remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers. For investors, the company’s growing clinical experience and international expansion signal that telerobotic surgery may be approaching a commercial inflection point.
At the heart of the discussion is SS Innovations’ SSi Mantra system, which has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. The company’s installed base reached 244 SSi Mantra systems as of the same date, up 45% from the end of 2025, while cumulative procedures totaled 14,503. These figures underscore not only adoption but also the system’s reliability across a range of surgical disciplines.
Dr. Sudhir Srivastava, founder and CEO of SS Innovations, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the key technical challenge is determining how much distance can be introduced without compromising responsiveness. That insight frames the company’s strategy: as remote procedures gain ground, the ability to deliver consistent, low-latency performance over long distances becomes a competitive differentiator. The MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” explored these issues in depth, noting that regulatory frameworks in the United States have yet to fully accommodate telesurgery. The full article is available at https://ibn.fm/4ZLvL, and additional details can be found in the Read More>> coverage.
SS Innovations is not waiting for U.S. regulators. The company is actively pursuing U.S. FDA clearance and European Union CE marking, which would open significant new markets. Meanwhile, SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. This global footprint demonstrates that demand for advanced robotic surgery exists beyond traditional high-income markets, and that SS Innovations is building the clinical evidence and infrastructure needed to support broader adoption.
The implications for the surgical robotics market are substantial. Telerobotic surgery could extend specialized care to underserved regions, reduce travel burdens for patients, and enable expert surgeons to operate across borders. However, questions around liability, data security, and cross-border licensing remain. SS Innovations’ growing procedure volume and international expansion provide a real-world testing ground for these issues. As the company accumulates telesurgery experience, its data could inform regulatory decisions and shape standards for remote procedures worldwide.
For investors, SS Innovations offers exposure to a niche but rapidly evolving segment of medical technology. The company’s newsroom at https://ibn.fm/SSII provides ongoing updates. As telerobotic surgery moves from isolated demonstrations toward broader clinical and regulatory development, SS Innovations’ early lead and expanding installed base position it as a company to watch. The convergence of clinical need, technological capability, and regulatory progress suggests that remote surgery may soon become a standard option, and SS Innovations is working to ensure its SSi Mantra system is at the forefront of that shift.
